Dylan Morris is a venture capital investor at Insight Partners who trained as a computational biologist before entering venture, building models of immune cells at the intersection of biochemistry, molecular biophysics, and computer science, which now directly informs how he evaluates and supports data-heavy biology companies. He leads Insight's dedicated bio practice with a software-first lens, focusing on computational biology and technology-enabled drug discovery rather than traditional wet-lab-only therapeutics investing, and describes himself as a biomedical accelerationist whose goal is to end involuntary dying, one disease at a time.

• Deep interest in the intersection of artificial intelligence and biology, specifically how generative models can move beyond predicting protein structures to creating new sequences for specific functions. Viewed as a major leap forward, this enthusiasm extends to using AI for planning biological experiments and integrating it into the fundamental design of new medicines.
• Focus on programmable therapeutics and the shift toward curative medicine rather than just symptom management. Highlights advancements in gene editing, immunotherapy, and small molecules that can reprogram enzyme activity, often describing the current era as a time of miracles where the age of cures has finally arrived.
• Advocacy for accelerating the regulatory and clinical trial process to get treatments to patients faster. Champions innovations that modernize drug development, such as the use of AI-powered digital twins in clinical trials to streamline FDA approval, emphasizing that speed is a moral imperative in treating disease.
• Commitment to universally accessible healthcare and the removal of financial barriers for patients. Expresses strong opinions that health insurance systems are often flawed and argues that prescribed medicines should have zero copays to ensure equitable access to life-saving genomic therapies.
• Fascination with the structural and atomic understanding of biology. Shares excitement over technical milestones like achieving atomic representations of entire cells or moving from static structural analysis to understanding structural distributions, viewing these deep scientific insights as the bedrock for future medical breakthroughs.